Key regions: Australia, Italy, France, South Korea, Brazil
The availability and affordability of vaccines are crucial to the health and wellbeing of a population. Mozambique, a country in southeastern Africa, has made significant strides in improving its vaccination coverage in recent years.
Customer preferences: Mozambicans prioritize vaccines that protect against infectious diseases such as measles, polio, and yellow fever. The government has implemented national immunization campaigns and routine vaccination schedules to ensure the availability of vaccines to the general population, particularly children and pregnant women.
Trends in the market: The vaccines market in Mozambique has witnessed steady growth due to the government's efforts to increase vaccination coverage. The country has seen an increase in vaccine production and distribution, with the introduction of new vaccines such as pneumococcal conjugate vaccine (PCV) and rotavirus vaccine. Additionally, the government has partnered with international organizations to improve vaccine access and affordability.
Local special circumstances: Mozambique has faced several challenges in improving its vaccination coverage. The country has a large rural population with limited access to healthcare facilities, making it difficult to distribute vaccines to remote areas. Furthermore, the country has experienced political instability and natural disasters, which have hindered the implementation of vaccination campaigns.
Underlying macroeconomic factors: Mozambique is one of the poorest countries in the world, with a GDP per capita of less than $500. The government has limited resources to invest in healthcare infrastructure and vaccine development. However, the country has received significant financial support from international organizations such as Gavi, the Vaccine Alliance, to improve its vaccination coverage. The government has also implemented policies to encourage local vaccine production, which has helped to reduce vaccine costs and improve availability.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
